Park Soon-jae

Park Soon-jae

Park Soon-jae (#1612)

  • $ 3 B
  • Biopharmaceuticals
  • South Korea
  • M
  • 71 Years

About Me

Park Soon-jae is cofounder and CEO of South Korean biotechnology company Alteogen, which focuses on biosimilars and bio-betters. Alteogen is known for its ALT-B4, an enzyme with technology that allows drugs to be administered subcutaneously instead of intravenously. In 2024, Alteogen revealed Merck had agreed to a licensing deal to use ALT-B4 for the drug giant's cancer drug pembrolizumab. Alteogen shares soared 25% in a day following the announcement. Park's wife, Chung Hye-shin, served as the company's chief strategy officer until 2023.
About Images

Achievements

Career Highlights

A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped Park Soon-jae’s rise and global influence.

  • #22   Korea's 50 Richest (2026)
  • #1440   Billionaires (2026)

Wealth Growth

Net Worth Growth Over Time

Tracking Park Soon-jae’s net worth journey over the years, highlighting key growth phases and financial milestones.

Current Net Worth: $2.6B (May 4, 2026)